Lakewood-Amedex Biotherapeutics Inc. - What You Need to Know

Thinking about investing in Lakewood-Amedex? Before you put your money on the line, let’s break down what this company actually does in plain English. Here is the "friend-to-friend" guide to the deal.

1. What does this company do?

Lakewood-Amedex is a biotech company fighting germs. They are developing a new class of drugs called Bisphosphocins® to kill bacteria, viruses, and fungi—including "superbugs" that resist traditional antibiotics. While standard antibiotics target specific bacterial structures, Bisphosphocins destroy the bacterial cell membrane. The company believes this makes it harder for bacteria to develop resistance.

Their lead project, Nu-3, is a topical gel for diabetic foot ulcers. They are also testing their technology for UTIs and lung infections, such as those linked to cystic fibrosis. They aim to deliver medicine directly to the infection site, like through a gel or an inhaler. This approach concentrates the medicine where it is needed, which may reduce the side effects caused by drugs that circulate through the entire body.

2. How do they make money?

They do not sell any products yet, so they have no sales revenue. They are currently in the research phase, spending cash to run clinical trials and protect their patents.

As of September 30, 2025, they held about $658,000 in cash. However, they spend money quickly to stay in business; they spent over $3 million in the first nine months of 2025 alone. They currently owe more than they own in liquid assets. They have stated they must raise more money through selling stock or taking on debt just to keep operating and fund their trials.

3. How is this "Direct Listing" different from an IPO?

This is not a traditional IPO. In an IPO, a bank helps a company sell new shares to raise money and stabilizes the stock price. Lakewood-Amedex is doing a "Direct Listing." They are simply registering existing shares so current owners can sell them on the Nasdaq. The company receives no cash from this listing.

To get cash, they plan a separate private sale of "Series C Preferred Stock" to raise about $7.5 million. While this brings in money, it means more shares will eventually exist. This reduces your ownership percentage and dilutes the voting power of current shareholders.

4. What are the main risks?

Biotech investing is high-risk. Consider these factors:

• Clinical Trial Success: Their value depends entirely on trial results. If the FDA does not approve their products, the company’s value could collapse.
• Trial Bias: Some early trials are "open-label," meaning patients and doctors know the treatment being used. This can create bias, leading to results that might not hold up in stricter, double-blind trials.
• Cash Flow: They lose money consistently. If they cannot raise more cash or find partners, they may have to cancel their research.
• Logistics: Their products may need refrigeration. If the "cold chain" fails during shipping, the medicine could become ineffective.
• Volatility: There is no big bank acting as an underwriter to stabilize the stock price. Expect extreme price swings on the first day of trading.

5. The Details

• Exchange: Nasdaq Capital Market (Ticker: LABT)
• Stock Split: They performed a 1-for-5.92 reverse stock split in September 2025 to meet Nasdaq’s minimum price requirements.

Final Thought for Investors: This is a "pre-revenue" company, meaning they are essentially a science project with high costs and no current income. Because they are not raising money through this listing, you are buying shares from existing owners, not funding the company's research directly. If you decide to move forward, keep your position size small and be prepared for significant volatility.

Disclaimer: I am an AI, not a financial advisor. This is a high-risk, speculative investment. Never invest money you cannot afford to lose. Always read the official "Prospectus" on the SEC’s EDGAR website before deciding.